about
Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter studyToward a Biology-Driven Treatment Strategy for Peripheral T-cell LymphomaGlobal transcriptome analysis and enhancer landscape of human primary T follicular helper and T effector lymphocytes.PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitorsBone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.Peripheral T-cell lymphoma unspecified type presenting with a pneumothorax as the initial manifestation: A case report and literature review.Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experienceTargeting histone deacetylases in T-cell lymphoma.A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma.Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets.Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.An audit of patients with mature T-cell non-Hodgkin lymphoma by transplant status in Tasmania.Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas.Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplanRare case of T-cell lymphoma presenting as acute myelopathy.
P2860
Q31092020-5E992DD6-7FF4-477A-82A9-8F05B4443BB8Q33423816-82DBD830-55EE-4805-A8CE-848BBA92900CQ33434137-0DBC54B4-A254-45A1-9AB9-8526D9167E2AQ33670421-88BFB67E-DE0A-46FA-8CED-0557E0491208Q34444243-BF8AC287-1A84-4A4C-A6B1-4D6CCBC1084FQ34489388-F0B197AD-EFCA-4515-9F1A-37D4D9E9593CQ35038458-7D42B1C7-6742-4E9B-9BC9-84FAB0E2D580Q35989647-20F6400D-00E7-4E7A-886C-99A5FC6451E5Q37271019-86F45238-08CC-437D-A404-5E21586E2C63Q37622508-4653A57D-BEC6-4F0D-A7DC-7CA9F2F4B215Q38528166-46CD59CC-5A3D-46EF-AC6E-4D9189750D32Q38782072-208EEFB5-F3B2-48B0-B4A1-044589CBE078Q38868024-62B73927-132A-48CE-9638-66E23E8BBD8BQ38949798-FA0B6715-2506-4F4B-ABC6-7842E51F6395Q38998630-FA5964B7-4335-487D-B677-EC14F9817378Q39839569-319F6628-1047-4614-AEF1-82CAF5616BE8Q42943377-6FD573C9-B379-4F1D-8248-F121F4576AF8Q47147843-4FDE9763-A6E9-4C21-90F6-A543CD5A7AE9Q48665990-80AE65CA-2C51-4E98-BA21-ECCF623C7F8AQ49290997-F3E5FA33-BE01-422E-8240-79B7E74CFCEDQ49887083-DC55D37B-775F-42A1-B012-1B0DCE871F09Q50217130-F6227016-DA2D-4C81-B5A9-9AA4F5796ACAQ50791564-7E66CEE7-0C71-4921-AA92-B0C0BF9C1895Q52985786-74E5ECCF-4EF0-443F-A1A4-F26483FCE28AQ53724724-7ABD625E-5B19-4F49-AEA7-2EE13C319F92
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
How I treat the peripheral T-cell lymphomas
@ast
How I treat the peripheral T-cell lymphomas
@en
type
label
How I treat the peripheral T-cell lymphomas
@ast
How I treat the peripheral T-cell lymphomas
@en
prefLabel
How I treat the peripheral T-cell lymphomas
@ast
How I treat the peripheral T-cell lymphomas
@en
P2093
P2860
P1433
P1476
How I treat the peripheral T-cell lymphomas
@en
P2093
Alison J Moskowitz
Matthew A Lunning
Steven M Horwitz
P2860
P304
P356
10.1182/BLOOD-2013-12-516245
P407
P577
2014-03-10T00:00:00Z